Lysanne L.
- Country
- The Netherlands
- Department
- Pulmonology
Research Overview
- Pumitamig Versus Durvalumab After Concurrent Chemoradiation in Unresectable Stage III Non-Small Cell Lung Cancer Without Progression
- Phase 3 Randomized Open‑Label Study of ZL‑1310 versus Investigator‑Chosen Topotecan in Relapsed Small Cell Lung Cancer
- A Phase III Double-Blind, Placebo-Controlled Study of Adjuvant Durvalumab in Resected Stage IB-IIIA Non-Small Cell Lung Cancer with PD-L1 Expression ≥25%
Data & Insights
Has run more than one trial at 161 of 384 partner sites.
Specializations
Respiratory Medicine
Lysanne Lievense focuses on disorders of the lung and airway, addressing chronic and acute conditions that impact breathing function.
- Chronic Obstructive Pulmonary Disease
- Asthma
- Idiopathic Pulmonary Fibrosis
- Bronchiectasis
- Respiratory Infections
Research integrates novel therapeutic agents to improve lung function and reduce exacerbation frequency.
Thoracic Oncology
The investigator engages in clinical studies of malignant tumors originating in the chest cavity, emphasizing targeted and immunotherapeutic strategies.
- Non‑Small Cell Lung Cancer
- Small‑Cell Lung Cancer
- Mesothelioma
- Metastatic Lung Cancer
- PD‑L1 Positive Tumors
Efforts aim to extend survival and enhance quality of life for patients with advanced-stage disease.
Cardiovascular & Metabolic Health
Investigations address atherosclerotic disease, cardiac events, and metabolic risk factors that contribute to vascular pathology.
- Atherosclerotic Cardiovascular Disease
- Acute Myocardial Infarction
- Atrial Fibrillation
- Lipoprotein(a) Disorder
- Obesity‑Related Cardiovascular Risk
Studies evaluate anti‑inflammatory and lipid‑lowering interventions to mitigate cardiovascular outcomes.
Immune‑Mediated Dermatology
Work includes trials of inflammatory skin conditions driven by dysregulated immune pathways.
- Atopic Dermatitis
- Hidradenitis Suppurativa
- Vitiligo
- Cutaneous Lupus Erythematosus
- Severe Eczema
Therapeutic focus is on biologics and small molecules that modulate cytokine signaling.
Hematologic Malignancies
The investigator contributes to studies of blood‑forming system cancers, exploring targeted and combination regimens.
- Acute Myeloid Leukemia
- Chronic Lymphocytic Leukemia
- Multiple Myeloma
- Diffuse Large B‑Cell Lymphoma
- Mantle Cell Lymphoma
Objectives include improving remission depth and extending event‑free survival.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.